©KPMG. To
co.uk> cc

16/07/2008 09:01

Subje RE: Review of the consequences of additional private ct drugs for NHS care

Dear Control

I'm assuming that you've got the details, as your name appears on a list of attendees that has just been sent to me. Let me know if there's a problem - otherwise I look forward to meeting you this evening.

Kind regards,

----Original Message----

Sent: 14 July 2008 20:18

To:

Subject: Re: Review of the consequences of additional private drugs for


NHS care

Dear


Many thanks for this. I believe that Mike is attending a breakfast launch event for this as he is unable to make the evening launch - but I would be happy to come along on the 16th to hear the debate. We will of course be reading the paper carefully as part of the evidence base to help shape Mike's final recommendation to SofS.

Grateful if you could pass me on the relevant details.

Best wishes,



.co.uk>



CC

Subject

Review of the consequences of additional private drugs for NHS care



Over recent weeks KPMG has been working with Charles Clarke MP (former Home Secretary and Secretary of State for Education) to produce a paper on user charges in the UK public sector. The paper covers a number of sub-sectors, including health, and it examines the political, economic and ethical arguments for and against "co-payment". The paper is in its final stages and will be launched at an event in our London Office on the evening of 16 July 2008. If this is of interest to you, you would be very welcome to attend the launch. The subject matter is highly relevant to Professor Richards' review.

Kind regards,

Partner

Head of Public Sector & Healthcare KPMG London

Mobile: +44 (0)7920 Direct line (internal):

Direct line (external): +44 (0)20 7311

Fax: +44 (0)20 7311 4512

This email was received from the INTERNET and scanned by the Government Secure Intranet anti-virus service supplied by Cable&Wireless in partnership with MessageLabs. (CCTM Certificate Number 2006/04/0007.)

DH users see Email virus scanning on Delphi under Security in DH, for further details. In case of problems, please call the IT support helpdesk.

This email has been sent from KPMG LLP, a UK limited liability partnership (which is a subsidiary of KPMG Europe LLP), from KPMG Europe LLP or from one of the companies within KPMG LLP's control (which include KPMG Audit Plc, KPMG United Kingdom Plc and KPMG UK Limited), together "KPMG". KPMG Europe LLP does not provide services to clients. None of KPMG Europe LLP's subsidiaries have any authority to obligate or bind KPMG Europe LLP. This email is confidential and may be legally privileged. It is intended solely for the addressee. Access to this email by anyone else is unauthorised.

If you are not the addressee or an intended recipient or have not agreed with us the terms on which you are receiving this email any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on the contents of this email or its attachments, is at your own risk, prohibited and may be unlawful, and to the fullest extent permitted by law KPMG accepts no responsibility or liability to you. When addressed to our clients any opinions or advice contained in this email or its attachments are subject to the terms and conditions expressed in the governing KPMG client engagement letter. Anything in this email or its attachments which does not relate to KPMG's official business is neither given nor endorsed by KPMG.

KPMG Europe LLP, registered in England No 0C324045 Registered office: 8 Salisbury Square, London EC4Y 8BB

KPMG United Kingdom PLC, registered in England No 03513178 Registered office: 8 Salisbury Square, London EC4Y 8BB

KPMG UK Limited, registered in England No 3580549 Registered office: Aquis Court, 31 Fishpool Street, St Albans AL3 4RF

KPMG LLP, registered in England No 0C301540 Registered office: 8 Salisbury Square, London, EC4Y 8BB

KPMG Audit Pic, registered in England No 3110745 Registered office: 8 Salisbury Square, London EC4Y 8BB